News

The completion of construction will be followed by GMP certification at the provincial level, according to the company. The 53,000mt2 pre-extraction plant will perform initial processing of traditional

Operations at the 55,000ft2 GCP-compliant facility are expected to commence in August 2013. Novum chief executive officer Christopher Chamberlain said, "Like our other research facilities, it will provide

The grant will provide $2.2m over three years to develop a recombinant tetravalent dengue vaccine using VaxInnate’s proprietary technology, which includes genetically fusing vaccine antigens to the bacterial

As part of the agreement, KannaLife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding science is based on the licensed technology

The two primary endpoints of OSKIRA-1were evaluation of signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint referred to as modified Total

The company completed Phase I safety trial of NSI-566 stem cells in ALS and also won orphan drug designation. Upon FDA approval, a Phase II trial is scheduled

As per the agreement of Zovirax ointment, Valeant will supply Actavis with a generic version of its Zovirax ointment product and Actavis will market and distribute the product.

Three patients enrolled in the second dose level cohort completed the first treatment cycle and well tolerated the L-DOS47 therapy. Patients to be enrolled in the third cohort

The oral drug candidate APD334 is formulated to target the sphingosine 1-phosphate subtype 1 (S1P1) receptor believed to take part in the modulation of various biological responses. Arena